



Author Correction: Tau-targeting antisense oligonucleotide MAPT_{RX} in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-023-02326-3>. Published online 24 April 2023.

<https://doi.org/10.1038/s41591-023-02639-3>

Published online: 16 October 2023

Catherine J. Mummery¹, Anne Börjesson-Hanson, Daniel J. Blackburn, Everard G. B. Vijverberg, Peter Paul De Deyn, Simon Ducharme², Michael Jonsson, Anja Schneider, Juha O. Rinne³, Albert C. Ludolph, Ralf Bodenschatz, Holly Kordasiewicz, Eric E. Swayze⁴, Bethany Fitzsimmons, Laurence Mignon, Katrina M. Moore, Chris Yun, Tiffany Baumann, Dan Li, Daniel A. Norris⁵, Rebecca Crean, Danielle L. Graham, Ellen Huang, Elena Ratti, C. Frank Bennett, Candice Junge & Roger M. Lane

In the version of this article initially published, the affiliation for Daniel Blackburn was incomplete and has been amended to read “Sheffield Teaching Hospital NHS Foundation Trust, NIHR Sheffield Clinical Research Facility and NIHR Sheffield Biomedical Research Centre, Royal Hallamshire Hospital, Sheffield, UK” in the HTML and PDF versions of the article.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

Author Correction: High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-022-02199-y>. Published online 2 February 2023.

<https://doi.org/10.1038/s41591-023-02500-7>

Published online: 17 July 2023

Jeroen van Dorp¹, Christodoulos Pipinikas, Britt B. M. Suelmann, Niven Mehra, Nick van Dijk², Giovanni Marsico, Maurits L. van Montfoort, Sophie Hackinger, Linde M. Braaf, Tauanne Amarante, Charlene van Steenis, Kirsten McLay, Antonios Daletzakis, Daan van den Broek, Maaïke W. van de Kamp, Kees Hendricksen, Jeantine M. de Feijter, Thierry N. Boellaard, Richard P. Meijer, Antoine G. van der Heijden, Nitzan Rosenfeld, Bas W. G. van Rhijn, Greg Jones & Michiel S. van der Heijden³

In the version of this article initially published, the first name of Antoine G. van der Heijden was misspelled as “Toine” and has now been corrected in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023